OR WAIT null SECS
April 01, 2020
Daiichi Sankyo has entered into a partnership with Ultragenyx Pharmaceutical for the use of Ultragenyx’s proprietary AAV-based gene-therapy manufacturing technology.
The new patented process results in uniform, scalable production and the ability to deliver cell cargo similar to natural exosomes/extracellular vesicles.
March 24, 2020
Thermo Fisher is focused on investing to expand three specific areas of demand: biologics, cell and gene therapy, and drug product development and commercial capabilities.
March 15, 2020
In January 2020, the agency finalized six clinical development and manufacturing guidance documents and drafted new guidance on what would qualify new gene therapies as orphan drugs.
March 02, 2020
Tackling process development early on can better optimize manufacturing processes for emerging therapies.
The growing interest in developing cell and gene therapies has prompted industry investment to grow manufacturing capacity.
The last year has seen intense investment activity into raising cell and gene therapy manufacturing capacity.
February 19, 2020
The 135,000 square foot facility will be constructed over 18 months and is expected to be operational in 2021.
February 10, 2020
New funding brings competitors, and a leading healthcare products distributor, into the standardization effort.
February 06, 2020
The new facility includes six classified environment rooms with space to expand.